BioGaia Logo

BioGaia

Develops and commercializes clinically proven probiotics for digestive health across all life stages.

BIOG | ST

Overview

Corporate Details

ISIN(s):
SE0017769987 (+1 more)
LEI:
549300UBUJOY2L7TT361
Country:
Sweden
Address:
Box 3242, 103 64 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioGaia is a biotechnology company specializing in the research, development, and commercialization of probiotic products. Since its founding in 1990, the company has focused on developing clinically proven probiotics to support digestive health and overall well-being for all life stages. Its product portfolio is based on patented strains of Lactobacillus, with key offerings like the BioGaia Protectis® line. This includes probiotic drops for infants, which are researched to help with common digestive issues such as colic, constipation, and diarrhea. BioGaia positions itself as a science-driven leader in its field, providing products that help maintain a healthy intestinal microflora.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-22 08:00
Quarterly Report
Swedish 1.6 MB
2025-10-22 08:00
Quarterly Report
English 1.5 MB
2025-08-22 17:30
Post-Annual General Meeting Information
Extra bolagsstämma i BioGaia
Swedish 149.3 KB
2025-08-22 17:30
Board/Management Information
Extraordinary General Meeting of BioGaia
English 71.0 KB
2025-07-25 09:31
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i BioGaia AB (publ)
Swedish 169.8 KB
2025-07-25 09:31
Pre-Annual General Meeting Information
Notice to attend the Extraordinary General Meeting of BioGaia AB (publ)
English 199.0 KB
2025-07-18 08:01
Interim Report
Swedish 20.6 MB
2025-07-18 08:01
Interim Report
English 18.4 MB
2025-06-18 14:20
Major Shareholding Notification
Swedish 10.0 KB
2025-05-30 11:00
Declaration of Voting Results & Voting Rights Announcements
Förändrat antal röster i BioGaia AB (publ)
Swedish 261.2 KB
2025-05-30 11:00
Declaration of Voting Results & Voting Rights Announcements
Change in the number of votes in BioGaia AB (publ)
English 231.4 KB
2025-05-21 14:04
Declaration of Voting Results & Voting Rights Announcements
Swedish 10.0 KB
2025-05-20 13:01
Major Shareholding Notification
Swedish 10.7 KB
2025-05-14 16:43
Declaration of Voting Results & Voting Rights Announcements
Swedish 10.0 KB
2025-05-12 16:39
Major Shareholding Notification
Swedish 10.0 KB

Automate Your Workflow. Get a real-time feed of all BioGaia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioGaia

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioGaia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-08 Barbro Fridén Other Buy 188 19,627.20 SEK
2024-09-13 Linda Hägglund Other Sell 2,000 233,800.00 SEK
2024-09-12 Linda Hägglund Other Sell 994 115,502.80 SEK
2024-09-12 Linda Hägglund Other Sell 6 697.80 SEK
2024-06-10 Outi Armstrong Other Buy 1,000 125,400.00 SEK
2023-08-02 Anthon Jahreskog Other Buy 481 51,515.10 SEK
2023-08-02 Anthon Jahreskog Other Buy 169 18,083.00 SEK

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.